Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular spasm (MVS), both described as syndrome etiology.

To establish the cause of MINOCA, coronary provocation testing with intracoronary acetylcholine is considered a IIA indication. Specific treatments for these cases might improve patient quality of life, since they often relapse. However, at present, physicians fear potential complications. 

The aim of this study was to assess, through a systematic review and meta-analysis, the safety of coronary provocation testing with intracoronary acetylcholine (ACh) for the contemporary diagnosis of epicardial and microvascular spasm. Major complication was defined as a composite of death, ventricular tachycardia/fibrillation, myocardial infarction, or shock requiring reanimation. Minor complications were paroxysmal atrial fibrillation, ventricular extrasystole, transient hypotension or bradycardia requiring pacemaker implantation. 

This meta-analysis included a total of 16 studies with 12585 patients, the administration of 100 to 200mcg acetylcholine to the left coronary and the assessment of endothelial function with a short 36mcg infusion.

Read also: Prognostic Value of Structural and Functional Microvascular Dysfunction in Patients with Nonobstructive Coronary Artery Disease.

Major complications incidence was 0.5% (CI 95% 0.0-1.3%). There were no deaths. Subgroup analysis showed accumulated incidence of major complications was higher in studies where spasm cutoff value was ≥90% obstruction vs. prior diagnostic cutoff value of ≥75% (1.0%; CI 95% 0.3-2.0%); the incidence was significantly lower in western populations vs. Asian (0.0%; CI 95% 0.0%-0.45%).

When comparing the safety of different doses, major and minor complications rates were similar when using different acetylcholine doses ranging 100 to 200mcg.

Conclusions

Provocation testing with intracoronary acetylcholine resulted safe. There were differences in subgroups, western populations being the least affected. 

Despite the fact that this meta-analysis showed great study heterogeneity, it shows promise towards advancing acetylcholine routine protocols in the cath lab, to better diagnose VSA and MVS as causes of INOCA and MINOCA. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols.

Reference: Takahashi, Tatsunori et al. “Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols.” Journal of the American College of Cardiology vol. 79,24 (2022): 2367-2378. doi:10.1016/j.jacc.2022.03.385.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...